ANGPTL3 and metabolic dysfunction-associated steatohepatitis: In contrast, mutations in Angiopoietin-like 3 (ANGPTL3) lead to hypolipidemia (385), since circulating ANGPTL3 inhibits lipoprotein lipase and is positively associated with NASH (386).